Antibodies anti-HTLV III and lymphocyte subsets of high risk subjects. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Antibodies anti-HTLV III and lymphocyte subsets of high risk subjects.

Boll Ist Sieroter Milan. 1987;66(2):101-5. Unique Identifier : AIDSLINE MED/88024452
Ripa S; Mignini F; Anichini M; Casprini P; Prenna M; Department Cellular Biology, University of Camerino.

Abstract: 208 assay for the research into anti-HTLV III antibodies and lymphocytes subsets were carried out on the same number of patients at risk. 11 homosexual man, 143 intravenous drug users (i.d.u.) and 3 children of drug addicts from hospitals in the Marche and Abruzzo and 51 haemophiliacs from hospital in Florence were examined. 3 determination of anti-HTLV III antibodies were taken from each subject using 3 different commercial Kits. The results concur with and confirm similar epidemiological studies that have been done. The haemophiliac group had the highest positive percentage (39.2%), then came i.d.u. (11.9%) and the homosexuals (10.0%). Furthermore, of the 38 positive totals, there were 22 with only one kit, 18 with two, and 15 with all three. The evaluation of the lymphocyte subsets did not strictly correlate with the presence of the antiretrovirus antibodies.
Keywords: Acquired Immunodeficiency Syndrome/*ETIOLOGY/IMMUNOLOGY Adult Antibodies, Viral/*ANALYSIS Child Comparative Study Hemophilia/COMPLICATIONS Homosexuality Human HIV/*IMMUNOLOGY Lymphocytes/*CLASSIFICATION Male Risk Factors Substance Dependence/COMPLICATIONS JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDetiology/immunologyadultantibodies,viral/KWDanalysischildcomparativestudyhemophilia/complicationshomosexualityhumanhiv/KWDimmunologylymphocytes/KWDclassificationmaleriskfactorssubstancedependence/complicationsjournalarticle
880228
M8820359

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .